Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el miércoles 18/06/2025 al final de la jornada laboral. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
184
resultados
Última actualización
21/06/2025 [08:13:00]
Resultados 75 a 100 de 184
Resumen de: US2025161308A1
The present disclosure relates to a method of treating long-term sequelae of infection with SARS-CoV-2, also known as long COVID. More particularly, it discloses the method of treating long COVID, the method comprising administering to a patient in need thereof a therapeutically effective amount of a HGF/MET positive modulating agent.
Resumen de: US2025161262A1
Pharmaceutical compositions and methods for preventing, treating, relieving, or ameliorating symptoms of coronavirus infection, including COVID-19 and variants thereof, including treating or preventing severe illness from corona vims infection, comprising the administration of IMPDH inhibitors and/or restricted diets of guanosine-containing nucleosides or nucleotides.
Resumen de: WO2025106792A1
Provided herein is a stable mutant coronavirus spike protein stem domain in a prefusion conformation comprising: an S2 subunit only, that has been modified to comprise; at least one additional intra-monomeric disulfide bond that stabilizes the S2 subunit; and 1, 2, 3, 4, or 5 proline mutations for greater trimeric stability, wherein the mutant coronavirus pre-fusion, S2-only spike protein maintains the prefusion conformation. Coronavirus is SARS, MERS, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), SARS-CoV-2, existing variants, or an emerging variant thereof.
Resumen de: WO2025106425A1
The disclosure provides a composition comprising a nucleic acid encoding a human alpha coronavirus (HCoV) receptor binding domain (RBD) peptide and a severe acute respiratory syndrome coronavirus 2 (SCoV2) RBD peptide.
Resumen de: AU2023375894A1
The disclosure provides, in various embodiments, polypeptides (e.g, antibodies and antigen binding fragments thereof) that specifically bind to receptor binding domains (RBDs) of betacoronavirus Spike glycoproteins, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoproteins. The disclosure also provides, in various embodiments, fusion proteins comprising one or more of polypeptides, polynucleotides encoding polypeptides, vectors and host cells suitable for expressing polypeptides, and methods for treating viral infections (e.g., COVID-19).
Resumen de: US2025161431A1
This composition of this invention is comprised of live attenuated SARS-CoV-2 constructs as vaccines or research tools. Described herein is a highly attenuated SARS-CoV-2 with deleted accessory proteins and modified transcriptional regulator sequences (TRS) that can serve as a live-attenuated vaccine platform and a BSL-2 experimental system. Certain embodiments are directed to a live attenuated SARS-CoV-2 having a modified transcriptional regulatory sequence (TRS) and a deletion of one or more open reading frames selected from ORF3a, ORF3, ORF6, ORF7, and/or ORFS.
Resumen de: PH12022552054A1
The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.
Resumen de: EP4556021A1
The present disclosure provides a composition for inducing or maintaining an immune response against SARS-CoV-2 virus.
Resumen de: EP4556490A1
The present disclosure relates to a neutralizing antibody against SARS-coronavirus 2 (SARS-CoV2) or a variant virus thereof, or an antigen-binding fragment thereof. Since the neutralizing antibody of the present disclosure has inhibitory effect against SARS-coronavirus 2 and variants thereof (e.g., Delta variant, Omicron variant, etc.), it can be usefully used for prevention or treatment of infection by SARS-coronavirus 2 or variants thereof.
Resumen de: KR20250071176A
본 발명은 사스-코로나바이러스-2 (SARS-CoV-2) 범용 항원 아미노산 서열로 이루어진 폴리펩타이드 및 상기 폴리펩타이드를 암호화하는 폴리뉴클레오타이드에 관한 것이며, 상기 폴리펩타이드 또는 폴리뉴클레오타이드를 유효성분으로 포함하는 SARS-CoV-2 감염증 예방용 백신 조성물 및 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명은 와일드 타입의 SARS-CoV-2 및 현존하는 SARS-CoV-2 변이주뿐만 아니라 가상의 SARS-CoV-2 변이주에까지 대응할 수 있는 범용 항원 폴리펩타이드 및 이를 암호화하는 폴리뉴클레오타이드를 제공한다. 또한 본 발명은 상기 SARS-CoV-2 범용 항원 폴리펩타이드의 특정 위치의 아미노산을 치환함으로써 구조 안정성을 더욱 향상시킨 SARS-CoV-2 범용 항원 폴리펩타이드 및 이를 암호화하는 폴리뉴클레오타이드를 제공한다. 또한 본 발명은 상기 SARS-CoV-2 범용 항원 폴리펩타이드 또는 폴리뉴클레오타이드를 유효성분으로 포함하는 백신 및 약학적 조성물을 제공한다.
Resumen de: EP4556004A1
The present invention belongs to the field of compounds for use in therapeutic treatment, and more particularly hop derived compounds for use in the treatment of diseases caused by coronaviruses.The main field of application is human health, through the development of new active beta-acid-type antivirals against SARS-CoV-2The present invention relates to hop derived compounds according to the invention for use in the treatment of diseases caused by a virus chosen from coronaviruses belonging to the Coronaviridae family.
Resumen de: US12308098B1
A personal and reusable infection status passport device is disclosed that is configured to test for Covid-19 and infectious disease using photo and color analysis. The personal and reusable infection status passport device provides a supervisory testing unit/system to ensure testing is current and accurate. The quick and ease of use will allow for frequent testing so the individual will know their status without spending hours at a clinic or large sums of money on many single use tests. The test units are easier to produce and use with the main device. The device is capable of using a time stamp to ensure the test is current. The included processor and software will create a “status passport” system that will allow users to share their Covid-19 status as needed to comply with state, federal, local, and OSHA.
Resumen de: KR20250069453A
본 발명은 SARS-CoV-2 RBD 표적 HR2 펩타이드-융합 인간 항체의 활용 및 용도에 관한 것이다. 보다 구체적으로, 본 발명은 헵타드 반복 2 펩타이드(Heptad Repeat 2 Peptide, HR2) 및 코로나 바이러스의 수용체 결합 도메인과 특이적으로 결합하는 항체 또는 항원 결합 단편을 포함하는 단백질 복합체 및 이를 유효성분으로 포함하는, 코로나 바이러스 감염증의 치료용 약제학적 조성물에 관한 것이다. 본 발명의 상기 단백질 복합체는 잘 보존된 영역인 헵타드 반복 2 펩타이드를 코로나바이러스의 RBD 특이적 항체와 결합한 결과, 다양한 SARS-CoV-2 바이러스 변종에 대하여 독성없이 향상된 중화능을 나타내므로, 지속적으로 진화하는 SARS-CoV-2 변종에 효과적으로 대항할 수 있는 치료제 플랫폼으로써 유용하게 사용될 수 있다.
Resumen de: US2025152613A1
Provided herein are compositions for use in treatment fibrosis and in treatment of COVID-19, preferably moderate COVID-19, comprising Compound (1), or a pharmaceutically acceptable salt thereof. Also provided herein are methods for treatment of COVID-19, preferably moderate COVID-19 comprising administering to a patient in need thereof an amount of between 10 mg/day and 30 mg/day, of Compound (1).
Resumen de: US2025154204A1
The present invention relates to a novel reovirus-based vaccine platform, and confirmed that a part of the S1 gene of reovirus can be replaced with various exogenous epitope-encoding genes, and a recombinant reovirus manufactured according to the present invention not only can infect target cells and induce the expression of the epitope, but also can effectively prevent and treat diseases related to the epitope by activating the immune function of immune cells against the epitope. When using the reovirus-based vaccine platform of the present invention, vaccines containing various epitopes can be manufactured through relatively simple genetic manipulation technology, and can be administered in various ways including oral administration, so it can be utilized for the prevention and treatment of various infectious diseases including SARS-CoV-2 virus infection, and cancer.
Resumen de: US2025155436A1
Liquid composition for the preparation of a biological sample for methods for assaying for the presence of SARS-COV-2 or genetic variations (mutant) of SARS-COV-2 wildtype in said sample by POC PCR comprising: • a) a chaotropic salt, preferably guanidinium thiocyanate, in a concentration ranging from 1 to 90 mM and • b) optionally one or more RNAse inhibitor.
Resumen de: US2025155438A1
Systems and methods are disclosed herein for pathogen detection employing a lateral flow assay (LFA) device or ELISA assay, e.g. for detecting SARS-COV-2, the virus that causes COVID-19, in a sample. The LFA device includes a nitrocellulose membrane mounted on a solid support, a sample pad for receiving a sample, a conjugate pad containing gold nanoparticles conjugated to heavy chain antibodies (HcAbs), and an absorbent pad at the end of the device.
Resumen de: US2025154231A1
The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
Resumen de: AU2023366039A1
The present invention relates generally to compositions and methods for inhibiting the replication of coronaviruses and treating diseases caused by coronavirus infection. More specifically, the invention provides nucleic acids capable of inhibiting coronavirus (e.g. SARS-CoV-2) replication and their use in treating patients infected by the virus.
Resumen de: WO2025101653A1
Long COVID or Post Acute Sequelae of COVID-19 (PASC), is a prolonged, debilitating syndrome that follows acute SARS-CoV-2 infection in >10% of cases. Human bone marrow mesenchymal stem cell derived extracellular vesicles (hBM-MSC EVs) can present a new therapeutic option.
Resumen de: WO2025098545A1
The invention relates to small molecule inhibitors of formula (I) targeting the nsp14 protein of SARS- CoV-2 and other coronaviruses, for use as antiviral agents directly targeting viral proteins.
Resumen de: AU2023353862A1
The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants and other respiratory viruses that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protein, engineered nucleocapsid protein, engineered hemagglutinin protein, and/or engineered respiratory syncytial virus prefusion or fusion (RSV F) protein to the subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of spike-display, nucleocapsid-display, hemagglutinin-display, and/or RSV F-display vesicular vaccines designed to elicit strong humoral and cellular immune responses against multiple respiratory viruses and variants.
Resumen de: WO2025100882A1
The present invention discloses: a humanized ACE2-expressing transgenic mouse susceptible to SARS-CoV-2 virus infection, the mouse being obtained by applying a CRISPR system; and a method for producing same. The humanized ACE2-expressing transgenic mouse according to the present invention reflects the severity of symptoms, mortality patterns, and the like according to age, sex, viral infection dose, and the like, as observed in human COVID-19 cases, and reproduces immunopathological characteristics of SARS-CoV-2 infection in the lungs without viral replication or lesions in the brain, and thus can be effectively used to understand the pathogenesis of SARS-CoV-2 and to develop vaccines or therapeutic agents.
Resumen de: US2025152699A1
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
Nº publicación: US2025152697A1 15/05/2025
Solicitante:
ORGENESIS INC [US]
Orgenesis Inc
Resumen de: US2025152697A1
Disclosed herein are multi-antigenic autologous, cell-based SARS-CoV-2 vaccines comprising autologous antigen presenting cells (APCs) displaying at least two different SARS-CoV-2 antigens. These vaccines can be used to prevent SARS-CoV-2 infection or COVID-19. Further disclosed are methods for producing and using the vaccines.
BOPI
Sede Electrónica
